Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710
    4.
    发明申请
    Methods and compositions for treating cancer using 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 审中-公开
    用于治疗癌症的方法和组合物,使用2192,2133,6568,8895,9138,9217,9609,9857,9882,10025,20657,21163,25848,25968,32603,32670,33794,5446和94710

    公开(公告)号:US20070087375A1

    公开(公告)日:2007-04-19

    申请号:US11633986

    申请日:2006-12-05

    IPC分类号: C12Q1/68 G01N33/574

    摘要: The present invention relates to methods for the diagnosis and treatment of a cancer or cancer. Specifically, the present invention identifies the differential expression of 2192, 2193, 6568, 8895, 9138, 9217, 9609, 9857, 9882, 10025, 20657, 21163, 25848, 25968, 32603, 32670, 33794, 54476 and 94710 genes in tissues relating to cancer, relative to their expression in normal, or non-cancer disease states, and/or in response to manipulations relevant to a cancer. The present invention describes methods for the diagnostic evaluation and prognosis of various cancers, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating a cancer or cancer. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cancer.

    摘要翻译: 本发明涉及癌症或癌症的诊断和治疗方法。 具体而言,本发明鉴定组织中的2192,2133,6568,8895,9138,9217,9609,9857,9882,10025,20657,21163,25848,25968,32603,32670,3797,45476和94710基因的差异表达 涉及癌症,相对于它们在正常或非癌症疾病状态中的表达,和/或响应于与癌症相关的操作。 本发明描述了各种癌症的诊断评估和预后的方法,以及用于鉴定表现出这种病症倾向的受试者。 本发明还提供了鉴定能够调节癌症或癌症的化合物的方法。 本发明还提供了鉴定和治疗化合物作为癌症治疗的方法。

    3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor
    8.
    发明申请
    3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor 审中-公开
    3714,16742,23546和13887新型蛋白激酶分子及其用途

    公开(公告)号:US20070178515A1

    公开(公告)日:2007-08-02

    申请号:US11726163

    申请日:2007-03-21

    摘要: The invention provides isolated nucleic acids molecules, designated 3714, 16742, 23546, or 13887 nucleic acid molecules, which encode novel protein kinases. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 3714, 16742, 23546, or 13887 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 3714, 16742, 23546, or 13887 gene has been introduced or disrupted. The invention still further provides isolated 3714, 16742, 23546, or 13887 proteins, fusion proteins, antigenic peptides and anti-3714, -16742, -23546, or -13887 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供编码新的蛋白激酶的分离的核酸分子,命名为3714,16742,23546或13887核酸分子。 本发明还提供反义核酸分子,含有3714,16742,23546或13887核酸分子的重组表达载体,已经引入表达载体的宿主细胞,以及非人类转基因动物,其中3714,16742,23546或 13887基因已被引入或破坏。 本发明还进一步提供分离的3714,16742,23546或13887蛋白,融合蛋白,抗原肽和抗-3714,-16742,-23546或-13887抗体。 还提供了利用本发明组合物的诊断,筛选和治疗方法。

    Fluid control
    9.
    发明授权
    Fluid control 有权
    流体控制

    公开(公告)号:US08474484B2

    公开(公告)日:2013-07-02

    申请号:US12087255

    申请日:2006-12-29

    IPC分类号: F15D1/02

    摘要: A valve trim for a pressure reduction valve containing a plurality of high hydraulic flow resistance flowpaths therethrough. Each flowpath comprises at least two inlets (208, 209) and at least one impingement zone (210) having two zone inlets (211, 212) and two zone outlets (213, 214). The zone inlets (211, 212) communicate with the inlets (208, 209) and are arranged substantially 180 degrees to one another. The two zone outlets (213, 214) are arranged substantially perpendicular to the zone inlets (211, 212) such that flow entering the two zone inlets (211, 212) mutually impinges on itself creating an area of high energy loss, and thereafter separates and exits through the zone outlets (213, 214).

    摘要翻译: 一种用于减压阀的阀门装置,其包含通过其中的多个高液压阻力流路。 每个流路包括至少两个入口(208,209)和至少一个具有两个区域入口(211,212)和两个区域出口(213,214)的冲击区域(210)。 区域入口(211,212)与入口(208,209)连通并且彼此大致180度地布置。 两个区域出口(213,214)被布置成基本上垂直于区域入口(211,212),使得进入两个区域入口(211,212)的流相互撞击在自身上,形成高能量损失的区域,然后分离 并通过区域出口(213,214)离开。

    System for processing healthcare claim data
    10.
    发明授权
    System for processing healthcare claim data 有权
    处理医疗保险索赔数据的系统

    公开(公告)号:US07917378B2

    公开(公告)日:2011-03-29

    申请号:US10247980

    申请日:2002-09-20

    IPC分类号: G06Q40/00 G06Q10/00 G06Q50/00

    摘要: A claim pre-processing system employs trial adjudication to improve claim accuracy prior to claim submission to a healthcare payer institution or other entity. A system processes claim data related to provision of healthcare to a patient The system includes a claim data collator for collating data related to a claim for a particular patient for submission to a payer and a source of rules for use in processing collated claim data. A pre-processor submits the collated claim data for processing using the rules to validate the collated claim data is in condition for processing to initiate generation of payment. A claim processor submits the collated claim data to a payer, in response to successful validation by the pre-processor. A rules processor processes acquired claim data to identify a condition triggering application of a different set of rules for determining validity of an individual claim element. The pre-processor re-submits amended collated claim data for processing using the rules to validate the collated claim data is in condition for processing to initiate generation of payment, the amended collated claim data being received in response to unsuccessful validation using the rules.

    摘要翻译: 索赔预处理系统在提交给医疗支付机构或其他实体之前,采用审判裁决来提高索赔准确性。 系统处理与向患者提供医疗保健相关的索赔数据。该系统包括权利要求数据整理器,用于对与特定患者的权利要求相关的数据进行整理,以提交给付款人以及用于处理整理的索赔数据的规则来源。 预处理器使用规则提交整理的索赔数据进行处理,以验证整理的索赔数据处于开始生成付款的条件。 响应于预处理器的成功验证,索赔处理器将分类的索赔数据提交给付款人。 规则处理器处理获取的权利要求数据以识别触发应用不同的规则集合以确定个人权利要求元素的有效性的条件。 预处理器重新提交经修订的对照索赔数据,以便使用规则进行处理,以验证整理的索赔数据处于启动付款生成条件的条件下,修改后的整理索赔数据是响应于使用规则的不成功验证而收到的。